Target intelligence / Profile preview

Receptor tyrosine-protein kinase erbB-2 (HER2) extracellular domain II (HER2 ECD II)

Target
HER2 ECD II
Molecular classification
Receptor, Enzyme, Receptor tyrosine kinase, ErbB family, Type I transmembrane protein
01

Overview

Receptor tyrosine-protein kinase erbB-2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family, playing a pivotal role in regulating cell growth, survival, and differentiation (UniProt P04626). Unlike other ErbB receptors, HER2 does not have a known high-affinity ligand and remains in an open, constitutively active conformation that facilitates dimerization with other ligand-bound ErbB members. The extracellular domain II (ECD II) is the specific region responsible for this dimerization, particularly the formation of the HER2-HER3 heterodimer, which is considered the most potent signaling pair in the family. In many cancers, HER2 is overexpressed or amplified, leading to uncontrolled signaling and tumor progression. Drugs like pertuzumab specifically target ECD II to sterically hinder dimerization, effectively shutting down oncogenic signaling pathways and providing a targeted therapeutic approach for HER2-positive malignancies (FDA Label: Perjeta).

Other names
ErbB2NEUCD340Proto-oncogene NeuProto-oncogene c-ErbB-2Human epidermal growth factor receptor 2p185erbB2
02

Mechanism of action

Pertuzumab binds specifically to the extracellular dimerization domain (Domain II) of the HER2 protein, thereby blocking ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4 (FDA Label: Perjeta). This inhibition disrupts downstream signaling pathways such as the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, leading to growth arrest and apoptosis.

03

Biological functions

Signal transductionCell proliferationCell survivalHeterodimerizationProtein tyrosine kinase activity
04

Disease associations

CancerBreast cancerGastric cancerOvarian cancerNon-small cell lung cancer
05

Safety considerations

Left ventricular dysfunction (Cardiotoxicity)Embryo-fetal toxicityInfusion-related reactionsHypersensitivity and anaphylaxisDiarrhea (often associated with dual HER2 blockade)
06

Interacting drugs

07

Biomarkers

HER2 protein overexpression (IHC 3+)HER2 gene amplification (FISH/ISH positive)HER2 extracellular domain (sHER2) plasma levels

Beyond the preview

Go deeper on Receptor tyrosine-protein kinase erbB-2 (HER2) extracellular domain II (HER2 ECD II).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Receptor tyrosine-protein kinase erbB-2 (HER2) extracellular domain II (HER2 ECD II).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call